|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Thomas_J._Appio
|
|
gptkbp:countryOfOrigin
|
gptkb:Canada
|
|
gptkbp:formerName
|
gptkb:Valeant_Pharmaceuticals_International
|
|
gptkbp:founded
|
1959
|
|
gptkbp:headquartersLocation
|
gptkb:Laval,_Quebec,_Canada
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bausch Health Companies
|
|
gptkbp:industry
|
healthcare
pharmaceuticals
|
|
gptkbp:ISIN
|
CA0717341071
|
|
gptkbp:keyPerson
|
gptkb:Paul_S._Herendeen
gptkb:Robert_Spurr
gptkb:Thomas_J._Appio
Joseph C. Papa (former CEO)
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:market
|
neurology
dermatology
gastroenterology
eye health
consumer health products
|
|
gptkbp:memberState
|
over 100
|
|
gptkbp:netIncome
|
-$0.5 billion (2022)
|
|
gptkbp:notableEvent
|
Acquired Bausch & Lomb in 2013
Acquired Salix Pharmaceuticals in 2015
Valeant Pharmaceuticals rebranded as Bausch Health Companies in 2018
Involved in major price-gouging controversy (2015-2016)
Filed for bankruptcy in 1992 (as ICN Pharmaceuticals)
|
|
gptkbp:notableProduct
|
gptkb:Jublia
gptkb:Relistor
gptkb:Xifaxan
Bausch + Lomb eye health products
|
|
gptkbp:numberOfEmployees
|
~7,000 (2023)
|
|
gptkbp:parentCompany
|
gptkb:Bausch_+_Lomb
gptkb:OraPharma
gptkb:Salix_Pharmaceuticals
|
|
gptkbp:predecessor
|
gptkb:ICN_Pharmaceuticals
gptkb:Valeant_Pharmaceuticals_International
|
|
gptkbp:products
|
pharmaceuticals
medical devices
over-the-counter products
|
|
gptkbp:revenue
|
$8.12 billion (2022)
|
|
gptkbp:stockExchange
|
gptkb:NYSE
gptkb:TSX
|
|
gptkbp:stockSymbol
|
gptkb:BHC
|
|
gptkbp:subsidiary
|
gptkb:Bausch_+_Lomb
gptkb:OraPharma
gptkb:Salix_Pharmaceuticals
|
|
gptkbp:tradedOn
|
gptkb:NYSE:BHC
gptkb:TSX:BHC
|
|
gptkbp:website
|
https://www.bauschhealth.com/
|
|
gptkbp:bfsParent
|
gptkb:Bausch_&_Lomb
|
|
gptkbp:bfsLayer
|
5
|